Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Update on the clinical utility and optimal use of cefditoren.

Barberán J, Aguilar L, Giménez MJ.

Int J Gen Med. 2012;5:455-64. doi: 10.2147/IJGM.S25989. Epub 2012 May 21.

2.

Cefditoren in upper and lower community-acquired respiratory tract infections.

Soriano F, Giménez MJ, Aguilar L.

Drug Des Devel Ther. 2011 Feb 9;5:85-94. doi: 10.2147/DDDT.S9499. Review.

3.

Safety profile of cefditoren. A pooled analysis of data from clinical trials in community-acquired respiratory tract infections.

Granizo JJ, Aguilar L, Gimenez MJ, Coronel P, Gimeno M, Prieto J.

Rev Esp Quimioter. 2009 Jun;22(2):57-61.

4.

Cefditoren, a new aminothiazolyl cephalosporin.

Balbisi EA.

Pharmacotherapy. 2002 Oct;22(10):1278-93. Review.

PMID:
12389878
5.

Spotlight on cefditoren pivoxil in bacterial infections.

Wellington K, Curran MP.

Treat Respir Med. 2005;4(2):149-52. Review.

PMID:
15813670
6.

Cefditoren pivoxil: a review of its use in the treatment of bacterial infections.

Wellington K, Curran MP.

Drugs. 2004;64(22):2597-618. Review.

PMID:
15516158
7.

Review of cefditoren, an advanced-generation, broad-spectrum oral cephalosporin.

Guay DR.

Clin Ther. 2001 Dec;23(12):1924-37; discussion 1923. Review.

PMID:
11813929
8.

Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.

Biedenbach DJ, Jones RN.

Diagn Microbiol Infect Dis. 2009 Jun;64(2):202-12. doi: 10.1016/j.diagmicrobio.2009.01.017. Epub 2009 Mar 25. Review.

PMID:
19321284
9.

Antibiotic susceptibility of respiratory pathogens recently isolated in Italy: focus on cefditoren.

Tempera G, Furneri PM, Carlone NA, Cocuzza C, Rigoli R, Musumeci R, Pilloni AP, Prenna M, Tufano MA, Tullio V, Vitali LA, Nicoletti G.

J Chemother. 2010 Jun;22(3):153-9.

10.
11.

[Cefditoren and community-acquired lower respiratory tract infections (corrected)].

Barberán J, Mensa J.

Rev Esp Quimioter. 2009 Sep;22(3):144-50. Review. Spanish. Erratum in: Rev Esp Quimioter. 2011 Mar;24(1):56.

12.
13.

Cefdinir: an advanced-generation, broad-spectrum oral cephalosporin.

Guay DR.

Clin Ther. 2002 Apr;24(4):473-89. Review.

PMID:
12017394
14.

Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.

White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B.

J Antimicrob Chemother. 2004 Jan;53 Suppl 1:i3-20. Review.

PMID:
14726431
16.

Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.

Perry CM, Scott LJ.

Drugs. 2004;64(13):1433-64. Review.

PMID:
15212560
17.

Cefditoren in vitro activity and spectrum: a review of international studies using reference methods.

Jones RN, Pfaller MA, Jacobs MR, Appelbaum PC, Fuchs PC.

Diagn Microbiol Infect Dis. 2001 Sep-Oct;41(1-2):1-14. Review.

PMID:
11687308
20.

Diagnosis and treatment of upper respiratory tract infections in the primary care setting.

Fendrick AM, Saint S, Brook I, Jacobs MR, Pelton S, Sethi S.

Clin Ther. 2001 Oct;23(10):1683-706. Review.

PMID:
11726004

Supplemental Content

Support Center